Aura Health Inc. (the "Company" or “Aura”) (CSE:BUZZ) is pleased to announce that the Company has entered into a strategic PR campaign in Western Canada with R. Ian Cochrane. Mr. Cochrane brings three decades of marketing small and microcap companies in Western Canada. He will be an important asset in increasing the wherewithal of Aura in the western provinces.

Aura will compensate Mr. Cochrane by granting 350,000 stock options of the Company (the “Options”) on January 17, 2019 exercisable at $0.235. 200,000 Options shall vest immediately with 150,000 Options to vest on April 17, 2019. The Options shall expire on January 17, 2021.

The company is also pleased to announce the grant of 200,000 Options to Joel Freudman, Aura’s independent director and Chair of the Board of Director’s Audit Committee, on January 17, 2019. Since entering into the role in October 2018, Mr. Freudman has played an important role in guiding the company in audit and finance related issues. The Options shall be exercisable at $0.235, will vest immediately, and expire on January 17, 2021.

About Aura Health Inc.

Aura Health is building an international network of vertically integrated cannabis assets. Through an established product line of cannabis-infused edible products and oil extracts, Aura is dedicated to building a high margin downstream business in the medical marijuana sector. The company holds convertible debt that converts to 54% equity of HolyCanna, a cultivation and nursery license holder in Israel. The company also owns a 30% interest in four medical marijuana clinics in the U.S. Sun Belt.

For further information, please contact:

Daniel Cohen, CEO Aura Health Inc. (647) 202-1824

David Posner, ChairmanAura Health Inc. (647) 985-6727

Caution Regarding Forward-Looking Information:

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Such statements include submission of the relevant documentation within the required timeframe and to the satisfaction of the relevant regulators, completing the acquisition of the applicable real estate and raising sufficient financing to complete the Company's business strategy. There is no certainty that any of these events will occur. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.

The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulation S under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful.

Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

Pharmadrug (CSE:BUZZ)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Pharmadrug Charts.
Pharmadrug (CSE:BUZZ)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Pharmadrug Charts.